Duchenne Muscular Dystrophy - Pipeline Review, H2 2020
![](/report_cover/2671/duchenne_muscular_dystrophy_pipeline_review_q4_2010_en.gif)
Duchenne Muscular Dystrophy - Pipeline Review, H2 2020
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H2 2020, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.
Duchenne muscular dystrophy (DMD) is a genetic disorder that causes muscles to gradually weaken over time. Signs and symptoms of DMD include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking. Risk factors include gender and family history. Treatment includes steroid medication, respiratory therapy and surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 5, 14, 11, 1, 59, 22 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 1, 12 and 2 molecules, respectively.
Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H2 2020, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.
Duchenne muscular dystrophy (DMD) is a genetic disorder that causes muscles to gradually weaken over time. Signs and symptoms of DMD include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking. Risk factors include gender and family history. Treatment includes steroid medication, respiratory therapy and surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 5, 14, 11, 1, 59, 22 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 1, 12 and 2 molecules, respectively.
Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Duchenne Muscular Dystrophy - Overview
Duchenne Muscular Dystrophy - Therapeutics Development
Duchenne Muscular Dystrophy - Therapeutics Assessment
Duchenne Muscular Dystrophy - Companies Involved in Therapeutics Development
Duchenne Muscular Dystrophy - Drug Profiles
Duchenne Muscular Dystrophy - Dormant Projects
Duchenne Muscular Dystrophy - Discontinued Products
Duchenne Muscular Dystrophy - Product Development Milestones
Appendix
Duchenne Muscular Dystrophy - Overview
Duchenne Muscular Dystrophy - Therapeutics Development
Duchenne Muscular Dystrophy - Therapeutics Assessment
Duchenne Muscular Dystrophy - Companies Involved in Therapeutics Development
Duchenne Muscular Dystrophy - Drug Profiles
Duchenne Muscular Dystrophy - Dormant Projects
Duchenne Muscular Dystrophy - Discontinued Products
Duchenne Muscular Dystrophy - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development for Duchenne Muscular Dystrophy, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Target, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Duchenne Muscular Dystrophy - Pipeline by 4D Molecular Therapeutics Inc, H2 2020
Duchenne Muscular Dystrophy - Pipeline by AAVogen Inc, H2 2020
Duchenne Muscular Dystrophy - Pipeline by Akashi Therapeutics Inc, H2 2020
Duchenne Muscular Dystrophy - Pipeline by Alpha Anomeric, H2 2020
Duchenne Muscular Dystrophy - Pipeline by American CryoStem Corp, H2 2020
Duchenne Muscular Dystrophy - Dormant Projects, H2 2020
Duchenne Muscular Dystrophy - Dormant Projects, H2 2020 (Contd..1), H2 2020
Duchenne Muscular Dystrophy - Dormant Projects, H2 2020 (Contd..2), H2 2020
Duchenne Muscular Dystrophy - Dormant Projects, H2 2020 (Contd..3), H2 2020
Duchenne Muscular Dystrophy - Dormant Projects, H2 2020 (Contd..4), H2 2020
Duchenne Muscular Dystrophy - Discontinued Products, H2 2020
Duchenne Muscular Dystrophy - Discontinued Products, H2 2020 (Contd..1), H2 2020
Number of Products under Development for Duchenne Muscular Dystrophy, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Target, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Duchenne Muscular Dystrophy - Pipeline by 4D Molecular Therapeutics Inc, H2 2020
Duchenne Muscular Dystrophy - Pipeline by AAVogen Inc, H2 2020
Duchenne Muscular Dystrophy - Pipeline by Akashi Therapeutics Inc, H2 2020
Duchenne Muscular Dystrophy - Pipeline by Alpha Anomeric, H2 2020
Duchenne Muscular Dystrophy - Pipeline by American CryoStem Corp, H2 2020
Duchenne Muscular Dystrophy - Dormant Projects, H2 2020
Duchenne Muscular Dystrophy - Dormant Projects, H2 2020 (Contd..1), H2 2020
Duchenne Muscular Dystrophy - Dormant Projects, H2 2020 (Contd..2), H2 2020
Duchenne Muscular Dystrophy - Dormant Projects, H2 2020 (Contd..3), H2 2020
Duchenne Muscular Dystrophy - Dormant Projects, H2 2020 (Contd..4), H2 2020
Duchenne Muscular Dystrophy - Discontinued Products, H2 2020
Duchenne Muscular Dystrophy - Discontinued Products, H2 2020 (Contd..1), H2 2020
LIST OF FIGURES
Number of Products under Development for Duchenne Muscular Dystrophy, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
COMPANIES MENTIONED
4D Molecular Therapeutics Inc
AAVogen Inc
Akashi Therapeutics Inc
Alpha Anomeric
American CryoStem Corp
Anagenesis Biotechnologies SAS
Antisense Therapeutics Ltd
Armgo Pharma Inc
Audentes Therapeutics Inc
AUM LifeTech Inc
Avidity Biosciences Inc
Axolo Pharma Inc
Biogen Inc
BioIncept LLC
Bioleaders Corp
Biophytis SA
Capricor Therapeutics Inc
Catabasis Pharmaceuticals Inc
Consortium.AI
Constant Therapeutics LLC
CRISPR Therapeutics AG
Cumberland Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
DepYmed Inc
DMD Therapeutics Inc
DTx Pharma Inc
Dyne Therapeutics Inc
Dystrogen Therapeutics SA
Edgewise Therapeutics
Editas Medicine Inc
Eloxx Pharmaceuticals Inc
Epirium Bio Inc
Evox Therapeutics Ltd
FibroGen Inc
FibroGenesis LLC
Fulcrum Therapeutics Inc
Galapagos NV
GlaxoSmithKline Plc
InnoBioscience LLC
Italfarmaco SpA
Ixchel Pharma LLC
Keros Therapeutics Inc
LambdaGen Therapeutics
Milo Biotechnology LLC
Mitobridge Inc
Mitochon Pharmaceuticals Inc
MyoGene Bio LLC
Myos Inc
Myosana Therapeutics Inc
MyoTherix Inc
Nippon Shinyaku Co Ltd
OliPass Corporation
Oncotelic Inc
Pepgen Ltd
PeptiDream Inc
Pfizer Inc
PhaseBio Pharmaceuticals Inc
Pliant Therapeutics Inc
Progenitor Therapeutics Ltd
Prothelia Inc
PTC Therapeutics Inc
PYCTX Ltd
RASRx LLC
ReveraGen BioPharma Inc
Ridgeline Therapeutics LLC
Santhera Pharmaceuticals Holding AG
Sarcomed AB
Sarepta Therapeutics Inc
Solid Biosciences Inc
SOM Biotech SL
Stealth BioTherapeutics Corp
SteroTherapeutics LLC
Sutura Therapeutics Ltd
Taiho Pharmaceutical Co Ltd
Teijin Pharma Ltd
Tivorsan Pharmaceuticals Inc
Tolerion Inc
UGISense AG
Vertex Pharmaceuticals Inc
Vita Therapeutics Inc
Zata Pharmaceuticals Inc
Number of Products under Development for Duchenne Muscular Dystrophy, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
COMPANIES MENTIONED
4D Molecular Therapeutics Inc
AAVogen Inc
Akashi Therapeutics Inc
Alpha Anomeric
American CryoStem Corp
Anagenesis Biotechnologies SAS
Antisense Therapeutics Ltd
Armgo Pharma Inc
Audentes Therapeutics Inc
AUM LifeTech Inc
Avidity Biosciences Inc
Axolo Pharma Inc
Biogen Inc
BioIncept LLC
Bioleaders Corp
Biophytis SA
Capricor Therapeutics Inc
Catabasis Pharmaceuticals Inc
Consortium.AI
Constant Therapeutics LLC
CRISPR Therapeutics AG
Cumberland Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
DepYmed Inc
DMD Therapeutics Inc
DTx Pharma Inc
Dyne Therapeutics Inc
Dystrogen Therapeutics SA
Edgewise Therapeutics
Editas Medicine Inc
Eloxx Pharmaceuticals Inc
Epirium Bio Inc
Evox Therapeutics Ltd
FibroGen Inc
FibroGenesis LLC
Fulcrum Therapeutics Inc
Galapagos NV
GlaxoSmithKline Plc
InnoBioscience LLC
Italfarmaco SpA
Ixchel Pharma LLC
Keros Therapeutics Inc
LambdaGen Therapeutics
Milo Biotechnology LLC
Mitobridge Inc
Mitochon Pharmaceuticals Inc
MyoGene Bio LLC
Myos Inc
Myosana Therapeutics Inc
MyoTherix Inc
Nippon Shinyaku Co Ltd
OliPass Corporation
Oncotelic Inc
Pepgen Ltd
PeptiDream Inc
Pfizer Inc
PhaseBio Pharmaceuticals Inc
Pliant Therapeutics Inc
Progenitor Therapeutics Ltd
Prothelia Inc
PTC Therapeutics Inc
PYCTX Ltd
RASRx LLC
ReveraGen BioPharma Inc
Ridgeline Therapeutics LLC
Santhera Pharmaceuticals Holding AG
Sarcomed AB
Sarepta Therapeutics Inc
Solid Biosciences Inc
SOM Biotech SL
Stealth BioTherapeutics Corp
SteroTherapeutics LLC
Sutura Therapeutics Ltd
Taiho Pharmaceutical Co Ltd
Teijin Pharma Ltd
Tivorsan Pharmaceuticals Inc
Tolerion Inc
UGISense AG
Vertex Pharmaceuticals Inc
Vita Therapeutics Inc
Zata Pharmaceuticals Inc